Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00265759 · ClinicalTrials.gov registry record · Phase 3
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
A Phase 3 study, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 622
- Enrollment target
NCT00265759 is a Phase 3 study that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 622 participants.
The verdict
NCT00265759, a Phase 3 study, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 622 participants
- Enrollment target
Study Summary
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using exemestane, letrozole, or anastrozole, may fight breast cancer by lowering the amount of estrogen the body makes. Giving exemestane, letrozole, or anastrozole before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. It is not yet known whether exemestane, letrozole, or anastrozole is more effective in treating breast cancer. PURPOSE: This randomized phase III trial is studying exemestane, letrozole, and anastrozole to compare how well they work in treating postmenopausal women who are undergoing surgery for stage II or stage III breast cancer.
Interventions
- PROCEDURE Therapeutic Conventional Surgery
- DRUG letrozole
- DRUG anastrozole
- DRUG exemestane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 622 participants |
| Start Date | 2006-01 |
| Est. Completion | 2019-11-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00265759
The ClinicalTrials.gov registry entry for NCT00265759 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 622 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Therapeutic Conventional Surgery is the first listed.
NCT00265759 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00265759 about?
NCT00265759 is a clinical study titled "Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer". RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using exemestane, letrozole, or anastrozole, may fight breast cancer by lowering the amount of estrogen the body makes. Giving exemestane, letrozole, or anastrozole before surgery may make the tumor smaller and reduce t...
What is the current status of trial NCT00265759?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 622 participants. The study started on 2006-01. Estimated completion is 2019-11-27.
What interventions are being tested in trial NCT00265759?
The interventions under investigation include: Therapeutic Conventional Surgery (PROCEDURE), letrozole (DRUG), anastrozole (DRUG), exemestane (DRUG).
Who is sponsoring clinical trial NCT00265759?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.